PROGEN — Prostatype Genomics AB Income Statement
0.000.00%
Last trade - 00:00- SEK13.01m
- SEK3.59m
- SEK0.20m
Annual income statement for Prostatype Genomics AB, fiscal year end - December 31st, SEK millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 18 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | PRESS |
| Standards: | SAS | SAS | SAS | SAS | — |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 0.684 | 0.01 | 0.683 | 1.36 | 0.199 |
| Cost of Revenue | |||||
| Gross Profit | 3.92 | 2.51 | 0.683 | 3.73 | 1.92 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Depreciation and Amortization | |||||
| Other Operating Expenses | |||||
| Total Operating Expenses | 16.6 | 15.6 | 29.4 | 40.6 | 41.1 |
| Operating Profit | -15.9 | -15.5 | -28.7 | -39.2 | -40.9 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -17.4 | -15.6 | -29.1 | -41.4 | -41.1 |
| Net Income After Taxes | -17.4 | -15.6 | -29.1 | -41.4 | -41.1 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -17.4 | -15.6 | -29.1 | -41.4 | -41.1 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -17.4 | -15.6 | -29.1 | -41.4 | -41.1 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -127 | -100 | -128 | -155 | -6.12 |
| Dividends per Share |